ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Liver, Gallbladder, and Biliary Tract Cancers

Liver, Gallbladder, and Biliary Tract Cancers

Researchers from the National Cancer Institute are predicting that the rate of hepatocellular carcinoma (HCC) in the United States will likely decrease by the year 2030.

US-born Hispanics are more likely to get hepatocellular carcinoma and to die from chronic liver disease compared with their foreign-born counterparts.

Both radiofrequency ablation and stereotactic body radiotherapy are effective in the treatment of inoperable, non-metastatic hepatocellular carcinoma.

Adding the EGFR-targeting drug panitumumab to chemotherapy had no effect on survival in a group of patients with wild-type KRAS status advanced biliary tract cancer.

The presence of an abdominal blood clot may be a sign of cancer and may also be associated with poor survival for patients with pancreatic or liver cancers.

In this video, Dr. El-Khoueiry discusses results from a phase I/II study that suggest the PD-1 inhibitor nivolumab is safe and effective in advanced hepatocellular carcinoma.

Results from a phase I/II study suggest that the immunotherapy nivolumab is safe and effective in advanced hepatocellular carcinoma (HCC).

Pages

Subscribe to Liver, Gallbladder, and Biliary Tract Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.